94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Pharmacol.
Sec. Inflammation Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1568246
Ferroptosis and Hyperoxic Lung Injury: Insights into Pathophysiology and Treatment Approaches
Provisionally accepted- 1 Zigong First People's Hospital, Zigong, China
- 2 Zigong Academy of Medical Sciences, Zigong, Sichuan Province, China
- 3 Lanzhou University, Lanzhou, Gansu Province, China
- 4 Yibin Maternity and Children Hospital, Yibin, China
- 5 First Hospital of Lanzhou University, Lanzhou, Gansu Province, China
Hyperoxia therapy is a critical clinical intervention for both acute and chronic illnesses. However, prolonged exposure to high-concentration oxygen can cause lung injury. The mechanisms of hyperoxic lung injury (HLI) remain incompletely understood, and current treatment options are limited.Improving the safety of hyperoxia therapy has thus become an urgent priority. Ferroptosis, a novel form of regulated cell death characterized by iron accumulation and excessive lipid peroxidation, has been implicated in the pathogenesis of HLI, including diffuse alveolar damage, vascular endothelial injury, and bronchopulmonary dysplasia. In this review, we analyze the latest findings on ferroptosis and therapeutic strategies for HLI. Our aim is to provide new insights for the treatment of HLI and to facilitate the translation of these findings from bench to bedside.
Keywords: Hyperoxia, Lung Injury, ferroptosis, therapy, programmed cell death
Received: 29 Jan 2025; Accepted: 04 Mar 2025.
Copyright: © 2025 Qian, Zhou, Tian, Xiong and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Liu Qian, Zigong First People's Hospital, Zigong, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.